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Feasibility of a mitral annuloplasty with the capability for 
peri- and post-operative adjustment 
Abstract 
Surgical repair with implantation of a mitral annuloplasty ring is the gold standard 
treatment for mitral regurgitation. However, outcomes are variable and recurrent 
mitral regurgitation is not uncommon. A REshapeable Mitral Annuloplasty DevIce 
(REMADI) is proposed, which consists of a fully encapsulated low melting 
temperature alloy. The alloy is solid and rigid at body temperature and provides 
traction force to shape the annulus. When heated using a non-contact method, the 
alloy melts and the REMADI becomes malleable. The REMADI is engaged with the 
mitral valve annulus using anchors which automatically deploy upon contact. A 
passive beating porcine heart model was used to demonstrate the feasibility of the 
REMADI device, which was deployed, engaged, and used to reduce the diameter of 
the mitral valve annulus.  
Introduction 
Mitral regurgitation (MR) is a debilitating disease which affects 2% of the European 
adult population, with 250,000 new patients diagnosed worldwide per year [1]. MR is 
the predominant valvular pathology in Western populations, with an incidence which 
increases rapidly with age [2]. In the UK, 2,929 primary surgical mitral valve 
procedures were performed in 2015 [3], the majority of which were for the treatment 
of severe MR.  
The mitral valve apparatus consists of an annulus from which the two leaflets 
emanate. Chordae tendineae arising from the free edge of each leaflet are attached 
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to the papillary muscles of the left ventricle. Mitral regurgitation can arise from 
dysfunction of any of these components. Changes in the mitral valve, such as 
weakened leaflets and chordae, leads to primary mitral regurgitation and impaired 
systolic leaflet coaptation. In contrast, in secondary mitral regurgitation the mitral 
valve tissue is normal, but the supporting apparatus is altered. Generally, as the left 
ventricle becomes dilated and dyskinetic from ischemic or non-ischemic 
cardiomyopathies, the mitral valve leaflets fail to appose one another, leading to 
regurgitation [4]. In primary and secondary MR, systolic backflow of blood into the 
left atrium alters the ventricular pre-load and after-load. Initially these changes may 
be reversible, but with time irreversible decompensation occurs resulting in reduced 
contractility and symptoms of congestive heart failure. In primary MR the 
deterioration is gradual: 90% of the patients are alive at 8 years after diagnosis of 
MR, and 50% of these survive without any cardiac related events. In secondary MR, 
the intrinsic relationship between the mitral valve and left ventricle means that 
dysfunction of either structure begets further dysfunction such that transition is more 
rapid. Only 30% of patients survive to 5 years without a cardiac event [5].  
Current solutions 
Non-inotropic  and inotropic vasopressors, diuretics, vasodilators, and heart 
failure drugs have all been used to treat MR, but with no long term or reproducible 
success. As such, surgical intervention is the mainstay of treatment for MR. Given 
the complex nature of the mitral valve apparatus, various approaches are available 
to manage defects. The interaction between annulus, leaflets, chordae and ventricle 
has meant that complete valve replacement has been less successful, requires 
careful patient selection, and is generally avoided if possible. On the other hand, 
valve repair allows the dysfunctional portion of the valve apparatus to be corrected or 
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compensated for, typically by annuloplasty, leaflet resection, or neo-chordoplasty. 
The implantation of an annuloplasty ring is considered the gold standard for valve 
repair in functional/secondary MR, with a lower mortality rate, improved ventricular 
function, freedom from reoperation and anticoagulant complications, and superior 
long term survival than for replacement of the valve [6]. As such, repair is often the 
preferred intervention where possible.  
Carpentier first introduced the mitral annuloplasty ring in 1969 as a means of re-
shaping the annulus to improve leaflet coaptation [7]. The use of an undersized ring 
to reduce the annulus in secondary MR was first reported in 1995 [8]. Over this 
period, over 40 designs of mitral annuloplasty rings have been reported.  
Currently, a variety of surgical annuloplasty ring devices are available: they can be 
classified as rigid or flexible, and planar or saddle-shaped. Some rings may be of an 
‘incomplete’ C shape, extending around the posterior leaflet, and leaving a space 
across the base of the anterior leaflet. The physiological annulus is D-shaped when 
viewed axially and takes a saddle shape in 3-D space when loaded during systole. In 
vivo, in vitro, and in silico studies have suggested that augmenting the saddle form of 
the mitral valve annulus in a repair promotes optimum leaflet dynamics and reduces 
annular loading forces, promoting a more favorable outcome. While flexible rings 
may promote physiological dynamics, their lack of rigidity cannot provide the 
advantages conferred by a saddle form [9–11].  
The benefits of patient specific shaping  
Although mitral annuloplasty is superior to medical intervention and valve 
replacement, long term results after annuloplasty are still suboptimal, with recurrence 
of 2+ MR in 33% of the patients at 1 year, and 65% of the patients presenting with 
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recurrent MR at 2 years after surgery [12]. Current surgical mitral valve repair and 
replacement in severe ischemic MR carries a 20% mortality at 2 years. Among 
patients alive at 2 years following mitral valve repair, 60% have recurrent moderate 
or severe MR  [13]. Undersized ring annuloplasty may unevenly displace the 
posterior annulus anteriorly, which leads to increased loading of the posterior leaflet 
[14]. Essentially, the mitral valve becomes functionally unileaflet. Leaflet tethering 
decreases leaflet curvature and results in increased leaflet and chordal stress [15]. 
Using saddle-shaped rings which are accurately sized to patients’ mitral annulus 
directly affects the durability and effectiveness of mitral valve repairs [16]. Currently, 
a qualitative approach is taken to annuloplasty shaping and sizing. Advances in 
image acquisition allow high accuracy reconstructions of the mitral valve apparatus 
prior to intervention [9] and echocardiography and doppler allows repairs to be 
analyzed peri-operatively.  
Proposed solution 
We propose a mitral annuloplasty repair that is not fixed to a pre-set geometry, 
allowing peri-operative adjustment during the implantation procedure, and also post-
operative adjustment. Such a device would allow an optimum repair to be achieved, 
and could allow readjustment to ameliorate the effects of ventricular remodeling. To 
achieve this, the REshapeable Mitral Annuloplasty DevIce (REMADI) consisting of a 
fully encapsulated low melting temperature alloy. The alloy is solid and rigid at body 
temperature and provides traction to shape the annulus. When heated, the alloy 
melts and the REMADI becomes malleable.  
To enable the REMADI to be implanted percutaneously, attachment to the annulus is 
suture-less. We designed a set of anchors which automatically deploy when 
opposed to the tissue. Each anchor consists of two nickel titanium alloy barbs which 
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become embedded in the annular tissue. Prior to deployment the barbs are 
constrained within a stainless-steel sheaf. Upon apposition to the tissue surface, the 
sheaf retracts allowing the barbs to return to their original, curved conformations. 
The barbs become embedded within the mitral valve annulus, thereby securing the 
annuloplasty ring.  
There are several other devices for surgical, percutaneous or hybrid mitral valve 
repair which have been proposed, or have reached clinical testing. There is an array 
of devices of varying geometries, implantation methods, tissue attachment, and 
some with the facility to modify the geometry peri- or post-operatively; a selection of 
relevant devices are summarized in Table 1. While several of these devices have 
reached the first-in-man stage, there have been technical, clinical or commercial 
hurdles that have limited adoption. As a consequence, percutaneous repair of mitral 
regurgitation remains an unsolved problem.   
Table 1 Summary of direct and indirect mitral annuloplasty devices. 







Polyester pledglets for plication 
of the posterior annulus. No 
long-term adjustment. 
Not in clinical use since CE 







Adjustable posterior rigid band. 
No long-term adjustment. 
CE mark and 1 year trial 





Surgical implantation.  











Nitinol ring with pivoting 
First in human [20], multi-
center evaluation recruiting 
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anchors with planar circular 
geometry. 
No long-term adjustment. 
NCT02607527 
MitralFlex Surgically implanted ring 
deformable by cable. 
Animal feasibility study [21] 
Amend ring 
(Valcare). 
Transapical approach with 
expansion to a predetermined 
size. 
Rigid, planar, D-shaped ring.  
No long-term adjustment. 
First in human [22]. 
n/a Polycaprolactone ring with 
nickel–chromium alloy wire 
core, polyvinyl chloride tube 
coating, and polyester sewing 
cuff 





Reshaping device placed in 
coronary sinus via venous 
access. Inconsistent 
relationship between coronary 
sinus and mitral valve. 
Recruiting for multi-center 
randomized, double-blind 





Annuloplasty ring manufacture 
The annuloplasty ring is composed of a low melting temperature alloy core. A 
bismuth, indium, tin, zinc alloy (35, 48.6, 16, 0.4% weight respectively) was first 
proposed for biomedical uses in 2014 as a bone cement. The alloy melts at 57.5°C 
[24]. The encapsulating layer is a silicone elastomer MED-4420 (NuSil, Polymer 
Systems Technology Limited, UK). Appropriately sized rods were coated while 
rotating, before being cured in an environmental chamber at 50°C and 50% relative 
humidity for 24h. 
Prototype devices used for testing were constructed using non-vulcanized latex 
rubber (MBFG, Ireland). Appropriately sized mandrels were dip coated in rubber 
solution before being rotated around their long axis, for a minimum of 24h. The 
rubber tubes were then released from the mandrel. 
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Attachment of the annuloplasty device to the annulus tissue is achieved using nitinol 
barbs, shown in Figure 1 a and b. The barbs were laser cut from nickel titanium wire 
in their straight (pre-deployed) conformation and shape set to their curved (deployed) 
form. The shaft of the barbs is secured within the anchor by a welded collar. The 
anchor is laser cut from 316L stainless steel and consists of a ring through which the 
annuloplasty tube passes. The barbs are welded to the outer surface of the ring. 
Another stainless-steel tube is welded to the inner surface of the ring and is used to 
engage the annuloplasty device with the delivery tool. Six anchors are evenly spaced 
along the length of the annuloplasty tube and bonded to the rubber encapsulating 
layer using cyanoacrylate. 
The parts of the assembled device are illustrated in Figure 1 c and d. The rubber 
tube forms the encapsulating layer of the annuloplasty. The tubes were elongated by 
200%, filled with molten alloy and then cooled while in this extended state. The ends 
of the rubber tubes were sealed using custom stoppers (FormLabs Tough Resin V2).  
a           b         c  
Encapsulating rubber 
tube (either silicone 
elastomer or non-
vulcanized rubber in 
prototype devices) 
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d  
Figure 1 Schematic images of the annuloplasty and components. (a) Rib with anchor 
in pre deployed state, (b) rib with deployed anchor, (c) cross-section of annuloplasty 
ring, formed by injection filling of rubber tube with metal. (d) assembled device 
consisting of ring in a straight configuration with 6 ribs and barbs. 
Delivery device manufacture 
The prototype delivery tool was designed for in vitro catheter delivery. Six nitinol 
wires are used to form a basket. Axial compression of the nitinol wire members 
determines their radial displacement. Each member can be controlled individually, 
allowing non-circular shapes to be formed. The nitinol wires engage with the anchors 
of the annuloplasty device. The radial position of each spline can be controlled, and 
the axial position of each anchor with respect to each spline can be controlled, and 
as such any saddle form can be generated for the annuloplasty. 
Tissue apposition testing 
Engagement with the mitral annulus is achieved using the barbs. The force required 
to deploy and engage the barbs, and the force required to dehisce the barbs from 
the tissue were tested using a position controlled tensile tester (Texture Analyser, 
Stable Microsystems). Porcine hearts were obtained from a local abattoir and the 
mitral annulus dissected. The mitral annulus was restrained on the base plate using 
a Perspex sheet with a 10 mm hole through which the barb passed. Insertion and 
dehiscence were tested at a minimum of eight points on the atrial side of the mitral 
End 





tube with alloy metal 
core 
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annulus.  The force required to dehisce the barbs from the tissue was compared with 
force required to dehisce a 2-0 monofilament suture from the mitral annulus.  
Induction heating 
Non-contact heating of the mitral annuloplasty was performed using an inductor 
(FlexHeat 2.0, RDO Induction, NJ, USA). In this feasibility study, induction heating 
was performed with an external coil around the left atrium and pulmonary vein, as 
illustrated in Figure 2. The induction heater is driven by a 2 kW power supply.  The 
copper coil was internally cooled at a minimum flow rate of 2 Lmin-1. The heater 
module is tuned to the resonant frequency of the coil and load. The alternating 
current through the coil induces an alternating magnetic field, which is strongest 
within the coil, where the annuloplasty device is located. The alternating magnetic 
field penetrates the conductive alloy core of the annuloplasty, inducing eddy currents 
which heat the metal core of the annuloplasty through joule heating. This is used 
peri-operatively to soften the device and alter it from a straight configuration for 
delivery, to a C-shape for implantation, and then for any fine adjustment of the 
saddle form. This configuration of induction heating coil is incompatible with in-vivo 
testing, but allows a minimum induction current to be used for feasibility testing. The 
final device would utilize an internal coil mounted on the delivery catheter. 
 
10  J. Brubert 
 
 
Figure 2 Induction heating coil geometry for ex-vivo testing. Coil is formed from 9 
turns of 1/8” copper tubing, with a length, L, of 34mm; diameter, D, of 30mm. P1 
indicates the upstream pressure, P2 the ventricular pressure, P3 the aortic root 
pressure. AD indicates the implanted annuloplasty device. The flow is driven using 
the apical port, Ж. TA indicates the transapical port through which the catheter and 
device is introduced. 
Heat from the metal core of the annuloplasty ring will be dissipated through the 
encapsulating layer and into the environment.  
Passive heart simulation 
To test delivery and feasibility of the REMADI a porcine passive heart model was 
used [25] (Cardiac Biosimulator, LifeTec Group, Eindhoven, Netherlands). The 
passive heart model uses porcine hearts from a local abattoir. The hearts are frozen 
to reproduce their physiological mechanical properties. The hearts are mounted to 
the servo-controlled pump, in line with compliance and resistance modules to 
simulate pulsatile flow in the absence of active cardiac contraction. A port is placed 
at the apex, which provides the necessary pressure gradients to simulate diastolic 
and systolic flows through the heart. Without the requirement to pump blood, 
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Absolute and transvalvular differential pressure measurements were taken during 
testing.  
Results 
Tissue apposition testing 
The nitinol anchoring devices underwent in vitro testing to assess implantation and 
pullout force using a 2-0 polypropylene sutures as a control. A position-controlled 
tester implanted the anchors into a fresh porcine mitral annulus. Sample data from 
this experiment is shown in Figure 3. A single prototype anchor provided 2±0.5 N. 
The prototype device would be secured by a minimum of 6 anchors. Combined, the 
anchors would be sufficient to withstand the typical forces (1.2 ± 0.9N cyclic force, 
with a peak at 2.4 ± 4.5N) exerted upon a ring anchored in the mitral annulus under 
a systolic pressure of 150 mmHg [26]. The 2-0 polypropylene suture provided at 
least 10 N.  
 
Figure 3 Sample prototype barb insertion and pull-out force (N) for a single nitinol 
























Figure 4 REMADI mounted on the basket of the delivery catheter, with anchors in 
their pre-deployment state. 
 
Figure 5 Nitinol anchor in deployed position. 
Passive heart simulation 
A proof-of-concept REMADI was assembled to demonstrate the feasibility of the 
REMADI. Complete reversibility of the soft-rigid state allowed the REMADI to be 
shaped to fit into a catheter, and shaped to the annulus once in the left atrium. For 
proof-of-concept a 32Fr catheter was used. 
Four hearts were characterized on the passive heart platform. Gross and endoscopic 
images are shown in Figure 6 and Figure 7. Four implantations were performed. 
Three annuloplasties were implanted off-pump under direct vision with a trans atrial 
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the catheter delivery device through the apex of the left ventricle. There was an issue 
passing the chordae tendineae during the apical implantation, causing some 
damage. Figure 8 shows the ring being unsheathed within the left atrium. Once 
unsheathed, the induction heating system was used to soften the alloy core of the 
annuloplasty. The softened annuloplasty was then expanded using the basket, as 
shown in Figure 9. Retracting the annuloplasty device towards the apex brought the 
device into contact with the annulus. As the undeployed barbs make contact with the 
annulus, the restraining sheaths slide back into the device, allowing the barbs to 
become buried in the tissue of the annulus, as shown by the dissection image in 
Figure 11. With the REMADI attached to the annulus, the diameter of the device was 
reduced, and a saddle form produced. 
 
Figure 6 (l) passive beating heart simulator with pulmonary vein inflow, aortic 
outflow, and flow-driving apical port. Atrial view of mitral valve during systole (c) 
and diastole (r). 
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Figure 7 Ventricular view of mitral and aortic valves during systole. 
 
 
Figure 8 Endoscopic view of unsheathing of the REMADI from the left atrium 
during systole (l) and diastole (r). 
 
 
Figure 9 (L) With the REMADI in a softened state, the basket catheter can be 
expanded. (R) The ring engaged with the posterior annulus and disengaged from 
the delivery catheter. 
The left atrial pressure, left ventricular pressure, and transvalvular pressure 
gradients are shown in Figure 10. The minor difference between the traces may 
reflect a change in valve dynamics induced by the ring, but given that the baseline 
was a healthy, not a lesion model, no change in hydrodynamics was sought. The 
regurgitant fraction could not be accurately measured on this setup as it was not 
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possible to perform echocardiography, nor mount a high frequency ultrasonic flow 
probe on the pulmonary vein. Temperature probes placed in the annular tissue, and 
the left ventricle did not detect any change in temperature during heating. 
 








The REMADI device tested in this study was designed to represent the key 
components required for an assessment of feasibility. In this regard, could the device 
































TVPG with ring (mmHg) TVPG without (mmHg)
 
16  J. Brubert 
 
physiological flow (before and after engagement with the annulus), be shaped to a 
saddle form during delivery, engage with the mitral annulus, and provide a rigid 
deformation of the annulus. 
The barb devices described and tested in this paper are a novel means of implanting 
an annuloplasty device. The absolute pull-out strength has been characterized, and 
is of an appropriate order of magnitude, however the effect of cyclic stress upon the 
engagement between the anchor and tissue has not been tested.  Subsequent 
iterations of the REMADI would use a Dacron coating to promote full tissue 
integration into the mitral annulus. The design of the barbs of the anchors were 
optimized using linear estimates of the strain and stiffness. Finite element analysis 
may be used to optimize the dimensions of the barbs, whose dimensions are a 
critical factor for the overall profile of the device. A significant limitation of the barb 
method is the lack of control when deploying, and difficulty in retracting the barbs 
once deployed. The deployed barbs may be retracted, however this functionality is 
not built into the delivery device. Compared to the helical anchor method used by the 
Cardioband device [27], the REMADI anchors can be deployed more quickly.  
There are several shortcomings to the delivery device used for implantation of the 
REMADI. The form of the basket delivery tool impinges upon the mitral valve and 
prevents the leaflets from closing during systole. As such, the open basket impeded 
closure of the mitral valve. Optimization of the basket wire shapes can reduce this 
limitation in future designs. The transapical route of delivery permits direct access to 
the mitral valve which is necessary for this delivery device. It also affords larger bore 
access, fewer closure related complications, and avoids atherosclerotic peripheral 
vessels, however it is perceived as being more invasive than transfemoral delivery 
[28]. Table 1 shows several direct annuloplasty devices which are delivered via a 
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transseptal route  with transfemoral access, which has become the first choice of 
implantation method for valves [29]. The option for transfemoral implantation would 
be preferred, and may ease adoption of the device.   
In testing of the REMADI prototypes we encountered problems with the formation of 
cracks in the metal core upon re-freezing. To mitigate this issue the elastic 
encapsulating layer is overfilled, such that there is a positive pressure on the metal 
core. This is achieved by filling the encapsulating tube in an elongated state. 
Furthermore, the starting length of the encapsulating tube is less than the minimum 
desirable circumference of the mitral annulus; the device is stretched in order to 
engage with the mitral annulus before the remodeling step reduces both the device 
length and the annulus diameter. 
The effects of heating the device upon the surrounding tissues were a significant 
consideration in the design of the REMADI. While the core reaches temperatures in 
excess of 60°C, the encapsulating layer insulates the environment. The degree of 
insulation is limited by the thickness and thermomechanical properties of the 
material. The flow of blood past the device rapidly dissipates heat from the device. 
The assays that we have performed thus far have not been sensitive enough to 
detect any hemolysis or coagulation from this heating effect. The effects of relatively 
short contact times with relatively mild temperature increases have received little 
attention in the literature.  Seki et al., 2018 also tested the effects of heating a mitral 
annuloplasty, albeit to 40°C, with no indication of necrosis. The use of induction 
heating is not a common procedure, but there is precedence in the field: the 
enCorSQ MVR system (MiCardia) device uses induction to activate a phase change 
in nitinol [19]. The frequency of the inductor can be tuned to ensure maximum 
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energy transfer to the metal core. The penetration depth of the alternating magnetic 





where δ is the penetration depth (m), f is the frequency (Hz), μ is the magnetic 
permeability of the material (H/m), and σ is the electrical conductivity of the material 
(S/m). When the penetration depth exceeds the thickness of the material, eddy 
currents are not generated and there is minimal energy transfer. As such, smaller 
metal components such as the barbs, are not heated. 
Although the core of the REMADI does not make contact with any biological 
elements, nonetheless the material has been tested for its hemo- and 
biocompatibility, which are sufficient for long term implantation in accordance with 
ISO 10993 and published in [24]. The encapsulating layer is an elastomeric silicone 
material with ISO 10993 compliance for long term implantation in blood contacting 
devices. 
In this paper we demonstrated that the shape of the REMADI can be altered after 
implantation. As such, the REMADI could potentially accept a transcatheter mitral 
valve implantation (TMVI). Transitioning the prosthesis to a soft state allows the 
REMADI to conform to the perimeter of the valve implant, minimizing paravalvular 
leak and uneven TMVI expansion which may occur with rigid annuloplasty devices. 
The valve-in-ring concept emulates the accepted clinical pathway of transcatheter 
aortic valve implant (TAVI)-in-valve [30]. The second benefit of post-operative 
adjustment of a mitral annuloplasty ring is to reshape the annulus in a controlled 
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fashion to eliminate any subsequent recurrent mitral regurgitation, this has not been 
demonstrated in this paper, and requires the catheter to reengage with the device.  
Peri-operative adjustment of the mitral annuloplasty ring allows for patient specific 
optimization of the repair. The exact MR phenotype takes a different form in every 
patient [9], as such the ability to perform a patient specific annuloplasty (with peri-
operative feedback) may be of significant benefit. Carpentier described an optimal 
repair as (1) preserving or restoring full leaflet motion, (2) creating a large surface of 
coaptation, and (3) to remodeling and stabilizing the entire annulus [31]. Points (1) 
and (2) may be altered by manipulation of the annuloplasty ring after implantation 
which can be evaluated using peri-operative echocardiography. As such, the 
REMADI may confer a benefit over the other devices proposed elsewhere, as 
summarized in Table 1, which are not capable of long term adjustment and may only 
be adjusted to a pre-determined size.  
To complete testing of the REMADI, and demonstrate its effectiveness, further 
testing is warranted in a MR lesion model, both in vitro and in vivo. Finally, 
assessment of the durability of the REMADI and its components requires further 
evaluation.  
Conclusion 
The REMADI is a novel device for the treatment of mitral regurgitation with the 
capability to be reshaped peri-operatively to achieve an optimal saddle shaped 
conformation, and post-operatively to accept a transcatheter mitral valve. It may also 
be capable of post-operative adjustment to correct any future MR recurrence as a 
result of ventricular remodelling. The solid-liquid phase transition of a low melting 
temperature alloy is used to achieve a soft and rigid state allowing the device to fit 
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within a catheter, as well as adopt any required mitral annulus form. The nitinol 
anchor system has demonstrated feasibility to engage with mitral annular tissue and 
secure a device. The prototype REMADI was constructed, and then tested in a 
beating heart model where the annulus could be deformed by the device. 
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Figure 1 Schematic images of the annuloplasty and components. (a) Rib with anchor in pre 
deployed state, (b) rib with deployed anchor, (c) cross-section of annuloplasty ring, formed 
by injection filling of rubber tube with metal. (d) assembled device consisting of ring in a 
straight configuration with 6 ribs and barbs. 
Figure 2 Induction heating coil geometry for ex-vivo testing. Coil is formed from 9 turns of 
1/8” copper tubing, with a length, L, of 34mm; diameter, D, of 30mm. P1 indicates the 
upstream pressure, P2 the ventricular pressure, P3 the aortic root pressure. AD indicates the 
implanted annuloplasty device. The flow is driven using the apical port, Ж. TA indicates the 
transapical port through which the catheter and device is introduced. 
Figure 3 Sample prototype barb insertion and pull-out force (N) for a single nitinol barb. 
Distance is relative to the starting point of the barb, 11mm above the tissue. 
Figure 4 REMADI mounted on the basket of the delivery catheter, with anchors in their pre-
deployment state. 
Figure 5 Nitinol anchor in deployed position. 
Figure 6 (l) passive beating heart simulator with pulmonary vein inflow, aortic outflow, and 
flow-driving apical port. Atrial view of mitral valve during systole (c) and diastole (r). 
Figure 7 Ventricular view of mitral and aortic valves during systole. 
Figure 8 Endoscopic view of unsheathing of the REMADI from the left atrium during systole 
(l) and diastole (r). 
Figure 9 (L) With the REMADI in a softened state, the basket catheter can be expanded. (R) 
The ring engaged with the posterior annulus and disengaged from the delivery catheter. 
Figure 10 Transvalvular pressure gradient (TVPG) before and after implantation of an 
annuloplasty. 
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Table 1 Summary of direct and indirect mitral annuloplasty devices. 
 
